Aurobindo Strikes New Chinese JV As Beijing’s Reforms Gain Pace
Aurobindo has formed a new joint venture with a Chinese partner to supply products for the world’s second-largest pharmaceutical market, as Beijing’s drug procurement reforms gather pace.
You may also be interested in...
Indian stock market regulator SEBI has slapped the billionaire founder of Aurobindo Pharma, along with other promoters of the company, with a more than $3m fine for allegedly violating insider trading norms over a string of licensing agreements with multinational Pfizer.
RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.
Sun Pharma continues to build its global specialty business with an increasing focus on China and Japan. As it revealed first-quarter results, the company announced a licensing deal with CMS and a new leader for its operations in China.